The Drug Information Association
(DIA) has just appointed Jonathan Sheldon, Ph.D., Global Vice
President, Healthcare, Oracle Health Sciences*, to its Board of Directors for a
three year term.
Founded in 1964, DIA is an international, nonprofit,
multidisciplinary association that fosters innovation for improved health and
well-being worldwide. The association offers
knowledge resources and forums on product development, regulatory science, and
therapeutic innovation for professionals in the pharmaceutical, biotechnology,
and medical device communities.
Currently, fostering innovation
for improved worldwide health is clearly focused on Precision Medicine initiatives
-- both in the US and around the world. Precision Medicine requires
sophisticated, shared, scalable, and secure molecular data analysis
capabilities. Dr. Sheldon, with his expertise in areas of translational medicine and personalized healthcare, was
appointed to the DIA Board to share his insights on precision medicine analytics,
healthcare innovation, and data knowledge-sharing/organizing distribution on a
“Today, Precision Medicine is the
new watch-phrase in medical research and practice. Playing an ever-larger role
in drug development and healthcare outcomes, it can help DIA to advance its
vision of improved global health through innovation,” said Dr. Sheldon. “Precision
Medicine provides the molecular tools to stratify patients in a way that
optimizes trial design, and therefore, improves chances for clinical success.
DIA, as a global health knowledge exchange, can advance the innovations
associated with Precision Medicine through its forums and resources with the
hopeful result of saving more lives across the world. “
As part of his responsibilities, Dr. Sheldon, along all board members,will help the DIA to:
perspective to the DIA Board.
* Jonathan Sheldon, Ph.D., is
Global Vice President Healthcare. He is responsible for Oracle’s healthcare
business globally within the Health Sciences Global Business Unit, which
includes solutions in the areas of precision medicine, population health, and convergence with Life
Sciences. Previously, Dr. Sheldon has held positions of both Chief Scientific Officer
and Chief Technology Officer in software companies serving both life science
and healthcare sectors where he has lead the company's overall strategic
direction. Prior to the software business, he also established the first
bioinformatics group and was Head of Bioinformatics for five years at Roche
(UK) Pharmaceuticals. Dr. Sheldon has served on various advisory groups
including the Board of Directors of the Transmart Foundation.